These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 787016)

  • 1. A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma.
    Bellet RE; Catalano RB; Danna VG; Berd DA; Berkelhammer J; Mastrangelo MJ
    J Clin Pharmacol; 1976; 16(8-9):433-8. PubMed ID: 787016
    [No Abstract]   [Full Text] [Related]  

  • 2. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
    Bakowski MT
    Cancer Treat Rev; 1976 Jun; 3(2):95-107. PubMed ID: 821609
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
    Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J
    Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
    Bellet RE; Engstrom PF; Catalano RB; Creech RH; Mastrangelo MJ
    Cancer Treat Rep; 1976 Sep; 60(9):1395-7. PubMed ID: 1016973
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
    Flannery EP; Corder MP; Sheehan WW; Pajak TF; Bateman JR
    Cancer Treat Rep; 1978 Mar; 62(3):465-7. PubMed ID: 348318
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
    Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
    [No Abstract]   [Full Text] [Related]  

  • 7. A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
    Corder MP; McFadden DB; Bell SJ
    Cancer; 1984 Oct; 54(8):1496-8. PubMed ID: 6383594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma.
    Paul AR; Catalano RB; Engstrom PF
    Cancer Treat Rep; 1980; 64(10-11):1047-9. PubMed ID: 7006805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICRF-159: current status and clinical prospects.
    Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
    Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
    Rhomberg W; Mesche E; Gefeller D; Hassenstein E
    Strahlentherapie Sonderb; 1978; 75():110-4. PubMed ID: 400195
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report.
    Kvols LK; Eagan RT; Myers RP
    Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of ICRF-159 in refractory metastatic breast cancer.
    Creech RH; Engstrom PF; Harris DT; Catalano RB; Bellet RE
    Cancer Treat Rep; 1979 Jan; 63(1):111-4. PubMed ID: 369681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.
    Brubaker LH; Vogel CL; Einhorn LH; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):915-6. PubMed ID: 3087618
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
    Bonomi P; Yordan E; Blessing JA
    Am J Clin Oncol; 1988 Feb; 11(1):1-2. PubMed ID: 3277372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination of radiation and razoxane (ICRF 159) in vivo.
    Hellmann K; Grimshaw MB; Hutchinson GE
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):109-13. PubMed ID: 632139
    [No Abstract]   [Full Text] [Related]  

  • 17. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
    Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I-II evaluation of razoxane (ICRF-159) and doxorubicin in gastrointestinal cancer. A Southeastern Cancer Study Group Trial.
    DeSimone PA; Greco FA; Omura GA; Bartolucci A
    Am J Clin Oncol; 1986 Jun; 9(3):185-6. PubMed ID: 3728369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study.
    Belloni C; Mangioni C; Bortolozzi G; Carinelli S; D'Incalci M; Maggioni A; Morasca L
    Oncology; 1983; 40(3):181-5. PubMed ID: 6341912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Razoxane (ICRF 159) in the treatment of psoriasis.
    Atherton DJ; Wells RS; Laurent MR; Williams YF
    Br J Dermatol; 1980 Mar; 102(3):307-17. PubMed ID: 7370178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.